View the slides for the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy

The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients&Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Cancer Medicine, EarlyView.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Increased diffuse BM 18F-FDG uptake can be attributed to both bone marrow MI and benign etiologies. A decision tree based on C5.0 algorithm, combining PET/CT imaging and clinical features, is of potential use in discriminating BM malignant infiltration from patients with increased diffuse BM uptake.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Based on our earlier research into the main characteristics and risk factors for infections in hospitalized patients with multiple myeloma, we created the numerical Multiple Myeloma Index for Risk of Infection (MMIRI) to predict infection in myeloma patients. The included factors that could influence the pathogenesis and incidence of infections were sex, performance status, Durie Salmon stage of disease, International Staging System, serum creatinine level, immune paresis, neutropenia, serum ferritin level, the presence of any catheters, disease duration, stable/progressive disease, and type of therapy. For each of these p...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Short Research Communication Source Type: research
Multiple myeloma (MM) is a neoplastic plasma cell disorder with high disease recurrence rates. Novel therapeutic approaches capable of improving outcomes in patients with MM are urgently required. The AKT signalling plays a critical regulatory role in MM pathophysiology, including survival, proliferation, metabolism, and has emerged as a key therapeutic target. Here, we identified a novel AKT inhibitor, HS1793, and defined its mechanism of action and clinical significance in MM. HS1793 disrupted the interaction between AKT and heat shock protein 90, resulting in protein phosphatase 2A-modulated phosphorylated-AKT (p-AKT) reduction.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research
After enhancing the bioavailability of curcumin using polymers, a group of Washington State University researchers proved that curcumin can increase bone growth by between 30% and 45%  in a matter of weeks: “The presence of curcumin in TCP results in enhanced bone formation after 6 weeks.” (Quoted from the abstract.) The researchers are currently testing other natural extracts as well, namely “aloe vera, saffron, Vitamin D, garlic, oregano and ginger [… ] that might help with bone disorders, including those that encourage bone growth or that have anti-inflammatory, infection control, or a...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll bone building bone formation curcumin myeloma Source Type: blogs
sanifar Raymond Lai Malignant cells cultured in three-dimensional (3D) models have been found to be phenotypically and biochemically different from their counterparts cultured conventionally. Since most of these studies employed solid tumor types, how 3D culture affects multiple myeloma (MM) cells is not well understood. Here, we compared MM cells (U266 and RPMI8226) in a 3D culture model with those in conventional culture. While the conventionally cultured cells were present in single cells or small clusters, MM-3D cells grew in large spheroids. We discovered that STAT3 was the pathway that was more activated in 3D ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conditions:   Hematologic Diseases;   Cachexia; Cancer;   Leukemia;   Myeloma;   Lymphoma;   Cancer Intervention:   Other: whole-body electromyostimulation Sponsor:   University of Erlangen-Nürnberg Medical School Recruiting
Source: - Category: Research Source Type: clinical trials
Nawrocki Although recent treatment advances have improved outcomes for patients with multiple myeloma (MM), the disease frequently becomes refractory to current therapies. MM thus remains incurable for most patients and new therapies are urgently needed. Oncolytic viruses are a promising new class of therapeutics that provide tumor-targeted therapy by specifically infecting and replicating within cancerous cells. Oncolytic therapy yields results from both direct killing of malignant cells and induction of an anti-tumor immune response. In this review, we will describe oncolytic viruses that are being tested for MM the...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In a first, a national cancer organization has issued formal guidelines recommending exercise as part of cancer treatment, for all cancer patients. The Clinical Oncology Society of Australia (COSA) is very clear on the directive. Its recommendations are: Exercise should be embedded as part of standard practice in cancer care and viewed as an adjunct therapy that helps counteract the adverse effects of cancer and its treatment. All members of the multi-disciplinary cancer team should promote physical activity and help their patients adhere to exercise guidelines. Best practice cancer care should include referral to an accr...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Exercise and Fitness Health Source Type: blogs
Characterization of intratumoral heterogeneity is critical to cancer therapy, as presence of phenotypically diverse cell populations commonly fuels relapse and resistance to treatment. Although genetic variation is a well-studied source of intratumoral heterogeneity, the functional impact of most genetic alterations remains unclear. Even less understood is the relative importance of other factors influencing heterogeneity, such as epigenetic state or tumor microenvironment. To investigate the relationship between genetic and transcriptional heterogeneity in a context of cancer progression, we devised a computational approa...
Source: Genome Research - Category: Genetics & Stem Cells Authors: Tags: METHOD Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Hematology | Immunotherapy | Learning | Myeloma | Universities & Medical Training | University of Pennsylvania